Eisai Co., Ltd. (ESAIY) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Tokyo, Japan. The current CEO is Haruo Naito.
ESAIY has IPO date of 2023-02-02, 11,067 full-time employees, listed on the Other OTC, a market capitalization of $9.03B.
Eisai Co., Ltd. is a Tokyo-based pharmaceutical company founded in 1941 that engages in the research, development, manufacture, and commercialization of prescription medications across multiple therapeutic areas. The company's product portfolio includes Dayvigo for insomnia, Lenvima for various cancers including thyroid and renal cell carcinoma, Aricept for Alzheimer's disease, Halaven for breast cancer, and Fycompa for epilepsy, among other medications addressing neurology, oncology, gastroenterology, and other specialties. Eisai maintains a strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin, an antibody drug conjugate. The company operates globally with a strong presence in Japan and serves both domestic and international markets through its research and manufacturing operations.
